A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
- Conditions
- Urothelial Cancer
- Interventions
- Biological: AvelumabOther: Best Supportive Care
- Registration Number
- NCT02603432
- Lead Sponsor
- Pfizer
- Brief Summary
The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of first-line chemotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 700
- Histologically confirmed, unresectable locally advanced or metastatic transitional cell carcinoma of the urothelium
- Stage IV disease at the start of first-line chemotherapy
- Measurable disease (per RECIST v1.1) prior to the start of first-line chemotherapy
- Prior first-line chemotherapy must have consisted of at least 4 cycles and no more than 6 cycles of gemcitabine + cisplatin and/or gemcitabine + carboplatin
- No evidence of progressive disease following completion of first-line chemotherapy (i.e., ongoing CR, PR, or SD per RECIST v1.1 guidelines )
- Prior adjuvant or neoadjuvant systemic therapy within 12 months of randomization
- Prior immunotherapy with IL-2, IFN-α, or an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA 4 antibody (including ipilimumab), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
- Persisting toxicity related to prior therapy (Grade >1 NCI CTCAE v4.0); however, alopecia, sensory neuropathy (Grade 2 or less), or other (Grade 2 or less) adverse events not constituting a safety risk based on the investigator's judgement are acceptable.
- Patients with known symptomatic central nervous system (CNS) metastases requiring steroids
- Diagnosis of any other malignancy within 5 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the breast or of the cervix, low grade prostate cancer on surveillance without any plans for treatment intervention, or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm A Avelumab Avelumab plus Best Supportive Care (BSC) Arm A Best Supportive Care Avelumab plus Best Supportive Care (BSC) Arm B Best Supportive Care Best Supportive Care (BSC) alone Following the planned interim analysis for this study, eligible patients in Arm B whose cancer has not worsened and are still in the "watch and wait" part of the study will be given the option to receive Avelumab plus BSC. Prior to this, Arm B patients received BSC alone. All patients who choose not to receive Avelumab will be discontinued.
- Primary Outcome Measures
Name Time Method Overall Survival (OS) From randomization to discontinuation from the study, death or date of censoring, whichever occurred first (for a maximum duration of 41 months) Overall survival was defined as the time (in months) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Objective Response as Assessed by Investigator From randomization to progression of disease, start of new anti-cancer therapy or discontinuation from study or death, whichever occurred first (for a maximum duration of 41 months) Investigator assessed objective response according to RECIST version 1.1, was defined as participants with confirmed best overall response of CR or PR. CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. A CR also required normalization of tumor marker levels and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions.
Duration of Response (DOR) as Assessed by Blinded Independent Central Review (BICR) First response subsequently confirmed to progression of disease or start of new anti-cancer therapy or discontinuation from the study or death, whichever occurred first (for a maximum duration of 41 months) BICR assessed DOR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of PD or death due to any cause. As per RECIST version 1.1, CR: complete disappearance of all target and non-target lesions, with exception of nodal disease sustained for 4 weeks. Any pathological lymph nodes reduced in short axis to \<10 mm. PR: at least 30% decrease in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions. PD for target disease: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study and relative increase of 20%, sum also demonstrated absolute increase of at least 5 mm. PD for non-target disease: unequivocal progression of pre-existing lesions and if overall tumor burden increased sufficiently to merit discontinuation of therapy. Appearance of any new unequivocal malignant lesion was also considered PD.
Percentage of Participants With Disease Control (DC) as Assessed by Blinded Independent Central Review (BICR) From randomization to PD, death or start of new anti-cancer therapy (for a maximum duration of 41 months) Disease Control (DC) was defined as a best overall response of CR, PR, non-CR/non-PD or stable disease (SD) as assessed by BICR. CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions. Non-CR/Non-PD was defined as persistence of any non-target lesions and/or tumor marker level above the normal limits. SD was defined as not to qualify for CR, PR or PD for target lesions and followed PR only if the sum increased by less than 20% from the nadir, but enough that a previously documented 30% decrease no longer holds.
Number of Participants With Treatment-Emergent Adverse Events (AEs) Graded Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03 For "Avelumab + Best Supportive Care (BSC)'' group: Day1 up to 90 days after last dose of study drug; for BSC group: Day1 up to 90 days after EOT visit (for a maximum duration of up to approximately 70 months for both groups) An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per NCI-CTCAE version 4.03, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Treatment-emergent AEs are events between first dose of study drug and up to 90 days after last dose of study drug or end of treatment (EOT) visit, that were absent before treatment or that worsened relative to pretreatment state.
Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) From randomization to date of progression of disease, discontinuation from the study, death or date of censoring, whichever occurred first (for a maximum duration of 41 months) BICR assessed PFS: Duration from randomization until disease progression (PD) or death. PD as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 was defined for target disease as at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute increase of at least 5 millimeters. For non-target disease: PD was defined as unequivocal progression of pre-existing lesions and if overall tumor burden increased sufficiently to merit discontinuation of therapy. Appearance of any new unequivocal malignant lesion was also considered PD. Analysis was performed using Kaplan-Meier. PFS data was censored on date of last adequate tumor assessment for participants with no event (PD or death), who started new anti-cancer therapy prior to an event or with an event after 2 or more missing tumor assessments.
Time to Tumor Response (TTR) as Assessed by Blinded Independent Central Review (BICR) From the date of randomization to the first documentation of objective response (CR or PR) (for a maximum duration of 41 months) TTR was defined, for participants with an objective response as the time from 'start date' to the first documentation of objective tumor response (CR or PR), which was confirmed subsequently. CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions.
Percentage of Participants With Disease Control (DC) as Assessed by Investigator From randomization to PD, death or start of new anti-cancer therapy (for a maximum duration of 41 months) DC was defined as a best overall response of CR, PR, non-CR/non-PD or SD as assessed by Investigator. CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. Additionally, normalization of tumor marker levels and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions. Non-CR/Non-PD was defined as persistence of any non-target lesions and/or tumor marker level above the normal limits. SD was defined as not to qualify for CR, PR or PD for target lesions and followed PR only if the sum increased by less than 20% from the nadir, but enough that a previously documented 30% decrease no longer holds.
Maximum Plasma Concentration (Cmax) of Avelumab End of avelumab infusion on Day 1 of Cycle 1, 2, 3, 5, 7, 9, 11, 13 and Day 15 of Cycle 1, 2, 3 (each cycle=28 days) The Lower Limit of Quantitation (LLQ) of avelumab was 0.20 micrograms (mcg)/milliliter (mL). Data for this outcome measure was not collected for reporting group "Best Supportive Care", since avelumab was not administered in this arm.
Number of ADA Ever Positive Participants For Each Serum of ADA Titers for Avelumab From randomization up to the 30-Day Follow-up visit (maximum duration of up to approximately 68 months) Serum samples were assayed for ADA using a validated analytical method. Number of ADA ever positive participants for each serum of ADA titer (60, 180, 540, 1620, 4860, 14580, and 131220) are reported.
Percentage of Participants With Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR) From randomization to progression of disease, start of new anti-cancer therapy or discontinuation from study or death, whichever occurred first (for a maximum duration of 41 months) BICR assessed objective response according to RECIST version 1.1, was defined as participants with confirmed best overall response of complete response (CR) or partial response (PR). CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 mm. PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions.
Progression-Free Survival (PFS) as Assessed by Investigator From randomization to date of progression of disease, discontinuation from the study, death or date of censoring, whichever occurred first (for a maximum duration of 41 months) Investigator assessed PFS: Duration from randomization to first documentation of PD or death, whichever occurred first. PD as per RECIST version 1.1 was defined for target disease as at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (this included baseline sum if that was smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute increase of at least 5 mm. For non-target disease: PD was defined as unequivocal progression of pre-existing lesions and if overall tumor burden increased sufficiently to merit discontinuation of therapy. Appearance of any new unequivocal malignant lesion was also considered PD. Analysis was performed using Kaplan-Meier. PFS data was censored on date of last adequate tumor assessment for participants with no event (PD or death), who started a new anti-cancer therapy prior to an event or with an event after 2 or more missing tumor assessments.
Time to Tumor Response (TTR) as Assessed by Investigator From the date of randomization to the first documentation of objective response (CR or PR) (for a maximum duration of 41 months) TTR was defined, for participants with an objective response as the time from 'start date' to the first documentation of objective tumor response (CR or PR). CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. A CR also required normalization of tumor marker levels and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions.
Duration of Response (DOR) as Assessed by Investigator First response subsequently confirmed to progression of disease or start of new anti-cancer therapy or discontinuation from the study or death, whichever occurred first (for a maximum duration of 41 months) Investigator assessed DOR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of PD or death due to any cause. As per RECIST version 1.1, CR: complete disappearance of all target and non-target lesions, with exception of nodal disease sustained for 4 weeks. Additionally, normalization of tumor marker levels and any pathological lymph nodes reduced in short axis to \<10 mm. PR: at least 30% decrease in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions. PD for target disease: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study and relative increase of 20%, sum also demonstrated absolute increase of at least 5 mm. PD for non-target disease: unequivocal progression of pre-existing lesions and if overall tumor burden increased sufficiently to merit discontinuation of therapy. Appearance of any new unequivocal malignant lesion was also considered PD.
Change From Baseline in Vital Signs - Blood Pressure at Day 1 of Cycle 2, 3, 4, 5, 6, 7 and End of Treatment (EOT) Visit Baseline (Day [D] 1 of Cycle [C] 1), Day 1 of Cycle 2, 3, 4, 5, 6, 7 , EOT visit (for a maximum duration of 41 months) (each cycle=28 days) Vital signs included blood pressure and pulse rate. Blood pressure included sitting diastolic blood pressure (DBP) and sitting systolic blood pressure (SBP).
Predose Plasma Concentration (Ctrough) of Avelumab Pre-dose (0 hour) on Day 1 of Cycle 1, 2, 3, 5, 7, 9, 11, 13 and Day 15 of Cycle 1, 2, 3 (each cycle=28 days) The LLQ of avelumab was 0.20 mcg/mL. Data for this outcome measure was not collected for reporting group "Best Supportive Care", since avelumab was not administered in this arm.
Number of Participants With Laboratory Abnormalities Greater Than or Equal to (>=) Grade 3 (G3), Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03 For "Avelumab + Best Supportive Care (BSC)'' group: Day1 up to 90 days after last dose of study drug; for BSC group: Day1 up to 90 days after EOT visit (for a maximum duration of up to approximately 70 months for both groups) Hematology (Anemia G3: hemoglobin\<8.0 grams per deciliter \[g/dL\],\<4.9 millimoles (mmol)/liter (L),\<80 g/L, transfusion indicated, Grade 4 \[G4\]: life-threatening consequences, urgent intervention indicated, Grade 5 \[G5\]: death; platelet count decreased-G3:\<50.0 to 25.0\*10\^9/L, G4: \<25.0\*10\^9/L; lymphocyte count decreased-G3:\<0.5-0.2\*10\^9/L, G4:\<0.2\*10\^9/L; neutrophil count decreased-G3:\<1.0 to 0.5\*10\^9 /L, G4:\<0.5\*10\^9/L). Chemistry (creatinine increased-G3:\>3.0 to 6.0\*upper limit of normal \[ULN\], G4:\>6.0\*ULN; serum amylase increased, lipase increased-G3:\>2.0- 5.0\*ULN, G4:\>5.0\*ULN. Aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\]-G3:\>5.0 to 20.0\*ULN, G4:\>20.0\*ULN\]. Blood bilirubin increased-\[G3:\>3.0 to 10.0\*ULN, G4:\>10.0\*ULN\], Creatine phosphokinase \[CPK\] increased- \[G3:\>5.0 to 10.0\*ULN, G4:\>10.0\*ULN\], Hyperglycemia-\[G3:\>250 to 500 mg/dL; \>13.9 to 27.8 mmol/L hospitalization indicated, G4:\>500 mg/DL; \>27.8 mmol/L life-threatening consequences\]).
Number of Participants With Neutralizing Antibodies (nAb) Against Avelumab by Never Positive and Ever Positive Status From randomization up to the 30-Day Follow-up visit (maximum duration of up to approximately 68 months) nAb against avelumab in serum samples was determined and reported separately for nAb never positive and nAb ever positive participants. Participants were considered nAb ever-positive if they had at least one positive nAb result at any time point during study and were otherwise considered negative.
Number of Participants With Programmed Death Receptor-1 Ligand 1 (PD-L1) Biomarker Expression in Tumor Tissue as Assessed by Immunohistochemistry (IHC) Up to 41 months at the time of the analysis PD-L1 assessment was performed using immunohistochemistry on pre-treatment tumor tissue samples. Participants were classified as having PD-L1 -positive status if at least one of the following three criteria were met: at least 25% of tumor cells stained for PD-L1, at least 25% of immune cells stained for PD-L1 if more than 1% of the tumor area contained immune cells, or 100% of immune cells stained for PD-L1 if no more than 1% of the tumor area contained immune cells.
Number of Participants With Cluster of Differentiation 8 (CD8) T Lymphocytes (Cytotoxic T Lymphocytes) Up to approximately 60 months Number of Participants With CD8 T Lymphocytes (Cytotoxic T lymphocytes) were presented in this outcome.
Change From Baseline in Vital Signs - Pulse Rate at Day 1 of Cycle 2, 3, 4, 5, 6, 7 and End of Treatment (EOT) Visit Baseline (Day [D] 1 of Cycle [C] 1), Day 1 of Cycle 2, 3, 4, 5, 6, 7 , EOT visit (for a maximum duration of 41 months) (each cycle=28 days) Vital signs included blood pressure and pulse rate. Changes from baseline in sitting pulse rate were summarized.
Time to Deterioration (TTD) Based on National Comprehensive Cancer Network- Functional Assessment of Cancer Therapy (NCCN-FACT) Bladder Symptom Index- 18 (FBlSI-18) Disease Related Symptoms-Physical Subscale (DRS-P) Scores From randomization up to the 90-Day Follow-up Visit (maximum duration of up to 41 months) NCCN-FACT FBlSI-18: an 18-item participant completed questionnaire, designed to assess impact of cancer therapy on urothelial cancer-related symptoms and quality of life based on numerical point scoring of symptoms/concerns. It included four subscales: Disease related symptoms-physical subscale with 9 items, disease related symptoms-emotional subscale with 2 items, treatment side effects subscale with 5 items, general function/well-being subscale with 2 items. Participants rated their level of symptoms for each item using 5-point scale ranging: 0=not at all to 4=very much. For items negatively framed, scores were reversed for analysis so that higher scores= good quality of life. DRS-P score: total 9 items, ranging from 0=severely symptomatic to 36= asymptomatic. Higher scores=better functioning or lower symptom burden. TTD: time from randomization to first time participant's score showed 3 point or greater decrease from baseline in FBlSI-DRS-P subscale for 2 consecutive assessments.
Number of Participants With Anti-Drug Antibodies (ADA) Against Avelumab by Never and Ever Positive Status From randomization up to the 30-Day Follow-up visit (maximum duration of up to approximately 68 months) ADA against avelumab in serum samples was determined and reported separately for ADA never positive and ADA ever positive participants. Participants were considered ADA ever-positive if they had at least one positive ADA result at any time point during study and were otherwise considered negative. Data for this outcome measure was not planned to be collected and analyzed for reporting arm "Best Supportive Care", since avelumab was not administered in this arm.
Change From Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Overall Health Utility Score at Cycle 6 Baseline, Day 1 of Cycle 6 (1 cycle=28 days) The EQ-5D-5L was a 6-item participant-completed questionnaire designed to assess health status in terms of a single utility score. There were 2 components to the EQ-5D-5L, a Health State Profile which had individuals rate their level of problems (none, slight, moderate, severe, extreme/unable) in 5 areas (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), and a Visual Analogue Scale (VAS) in which participant rated their overall health status from 0 (worst imaginable) to 100 (best imaginable). Published UK weights was used to create a single summary utility score. Utility scores range from -0.594 to 1, with low scores representing lower health status.
Change From Baseline in National Comprehensive Cancer Network- Functional Assessment of Cancer Therapy (NCCN-FACT) Bladder Symptom Index- 18 (FBlSI-18) Score at Day 1 of Cycle 6 Baseline, Day 1 of Cycle 6 (1 cycle=28 days) NCCN-FACT FBlSI-18 is an 18-item participant completed questionnaire, designed to assess impact of cancer therapy on urothelial cancer-related symptoms and quality of life based on numerical point scoring of symptoms/concerns. It included four subscales: Disease related symptoms- physical subscale with 9 items, disease related symptoms- emotional subscale with 2 items, treatment side effects subscale with 5 items and general function/well-being subscale with 2 items. Participants rated their level of symptoms for each item using 5-point scale ranging from 0=not at all to 4=very much. Items that were negatively framed, and the scores were reversed for analysis so that higher scores= good quality of life. Overall score: total of 18 items, ranging from 0=severely symptomatic to 72=asymptomatic. Higher scores= better functioning or lower symptom burden.
Change From Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) - Visual Analog Scale (VAS) Score at Cycle 6 Baseline, Day 1 of Cycle 6 (1 cycle=28 days) The EQ-5D-5L was a 6-item participant-completed questionnaire designed to assess health status in terms of a single utility score. There were 2 components to the EQ-5D-5L, a Health State Profile which had individuals rate their level of problems (none, slight, moderate, severe, extreme/unable) in 5 areas (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), and a Visual Analogue Scale (VAS) in which participant rated their overall health status from 0 (worst imaginable) to 100 (best imaginable), higher scores indicating a better health state.
Trial Locations
- Locations (360)
University of Washington Medical Center
🇺🇸Seattle, Washington, United States
Bildediagnostisk avdeling
🇳🇴Nordbyhagen, Norway
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Fundación CENIT para la Investigación en Neurociencias
🇦🇷Caba, Argentina
Centro Oncologico Riojano Integral (Cori)
🇦🇷La Rioja, Argentina
Chris O'Brien Lifehouse
🇦🇺Camperdown, New South Wales, Australia
Concord Hospital
🇦🇺Concord, New South Wales, Australia
Dubbo Base Hospital
🇦🇺Dubbo, New South Wales, Australia
Ramsay Pharmacy
🇦🇺Kogarah, New South Wales, Australia
St George Private Hospital
🇦🇺Kogarah, New South Wales, Australia
Epic Pharmacy
🇦🇺Lismore, New South Wales, Australia
North Coast Radiology St Vincents
🇦🇺Lismore, New South Wales, Australia
Northern Rivers Pathology Service
🇦🇺Lismore, New South Wales, Australia
St Vincent's Pathology Lismore
🇦🇺Lismore, New South Wales, Australia
Macquarie Medical Imaging
🇦🇺Macquarie University, New South Wales, Australia
Macquarie University Hospital Pharmacy
🇦🇺Macquarie University, New South Wales, Australia
The Murwillumbah Hospital
🇦🇺Murwillubah, New South Wales, Australia
The Tweed Hospital Pharmacy Department
🇦🇺Tweed Heads, New South Wales, Australia
The Tweed Hospital
🇦🇺Tweed Heads, New South Wales, Australia
Icon Cancer Care Wesley
🇦🇺Auchenflower, Queensland, Australia
Oncology Pharmacy
🇦🇺Birtinya, Queensland, Australia
Slade Health
🇦🇺Mount Waverley, Australia
Icon Cancer Care
🇦🇺South Brisbane, Queensland, Australia
Integrated Clinical Oncology Network (ICON) Corporate Office
🇦🇺South Brisbane, Queensland, Australia
Flinders Medical Centre
🇦🇺Bedford Park, South Australia, Australia
Ashford Cancer Centre Research
🇦🇺Kurralta park, South Australia, Australia
Ballarat Oncology & Haematology Services
🇦🇺Wendouree, Victoria, Australia
Eastern Health Clinical School
🇦🇺Box Hill, Victoria, Australia
Moorabbin Radiology
🇦🇺East Bentleigh, Victoria, Australia
St John of God Murdoch Hospital
🇦🇺Murdoch, Western Australia, Australia
Macquarie Heart
🇦🇺New South Wales, Australia
AZ Klina
🇧🇪Brasschaat, Belgium
CHU de Liège
🇧🇪Liège, Belgium
GZA Sint-Augustinus
🇧🇪Wilrijk, Belgium
ONCOSITE - Centro de Pesquisa Clinica em Oncologia
🇧🇷Ijui, RIO Grande DO SUL, Brazil
Associação Educadora São Carlos - AESC / Hospital Mãe de Deus
🇧🇷Porto Alegre, RS, Brazil
Associação Educadora São Carlos - AESC / Hospital Mãe de Deus - Ambulatório Quimioterapia
🇧🇷Porto Alegre, RS, Brazil
Associação Educadora São Carlos - AESC / Hospital Mãe de Deus - Centro de Abastecimento Farmaceut
🇧🇷Porto Alegre, RS, Brazil
Uniao Brasileira de Educacao e Assistencia / Hospital Sao Lucas da PUCRS
🇧🇷Porto Alegre, RS, Brazil
Fundação FPio XII Barretos
🇧🇷Barretos, SP, Brazil
Fundação Pio XII Barretos
🇧🇷Barretos, SP, Brazil
Fundacao Faculdade de Medicina / Instituto do Cancer do Estado de Sao Paulo - ICESP
🇧🇷Sao Paulo, SP, Brazil
Hospital Alemao Oswaldo Cruz
🇧🇷Sao Paulo, SP, Brazil
Centro Integrado de Pesquisa Clinica - CIP
🇧🇷São José do Rio Preto, SP, Brazil
Sociedade Beneficente de Senhoras Hospital Sírio Libanês/ Instituo Sirio Libanes de Ensino e Pesqu
🇧🇷São Paulo, Brazil
William Osler Health System
🇨🇦Brampton, Ontario, Canada
Princess Margaret Cancer Centre
🇨🇦Toronto, Ontario, Canada
Fakultni nemocnice Brno
🇨🇿Brno, Czechia
Fakultni nemocnice u sv. Anny v Brne
🇨🇿Brno, Czechia
Fakultni nemocnice u sv.Anny v Brne
🇨🇿Brno, Czechia
Nemocnice Horovice, NH Hospital a.s.
🇨🇿Horovice, Czechia
Nemocnice Horovice
🇨🇿Horovice, Czechia
CT-Klinikken A/S
🇩🇰Aarhus N, Denmark
Odense Universitetshospital
🇩🇰Odense, Denmark
Groupe hospitalier Pitie Saleptriere
🇫🇷Paris, Cedex 13, France
Institut de cancérologie de l'Ouest - Site Paul Papin
🇫🇷Angers, France
Clinique CAPIO Belharra
🇫🇷Bayonne, France
Hôpital Jean Minjoz
🇫🇷BESANCON cedex, France
CHU Besançon - Pharmacie Unite Essais cliniques
🇫🇷Besançon, France
CHU Besançon
🇫🇷Besançon, France
Hôpital Privé Toulon-Hyères - Clinique Sainte Marguerite
🇫🇷Hyères, France
Hôpital Henri Mondor
🇫🇷CRÉTEIL Cedex, France
Clinique Victor Hugo
🇫🇷Le Mans, France
Centre Oscar Lambret
🇫🇷Lille, France
Centre Léon Berard
🇫🇷LYON cedex 8, France
Institut Paoli Calmettes
🇫🇷Marseille, France
CHU Nimes - Hopital Caremeau
🇫🇷Nimes, France
CHU Nimes
🇫🇷Nimes Cedex 9, France
Centre Eugene Marquis
🇫🇷Rennes Cedex, France
Institut de Cancérologie de l'Ouest - Centre René Gauducheau
🇫🇷Saint Herblain Cedex, France
Centre de Radiothérapie - Clinique Sainte Anne
🇫🇷Strasbourg, France
Hopital Foch
🇫🇷Suresnes, France
Institut Gustave Roussy
🇫🇷Villejuif, France
Medical Center of Athens
🇬🇷Marousi, Athens, Greece
Metropolitan General Hospital
🇬🇷Athens, PC, Greece
University General Hospital of Patras, Division of Oncology
🇬🇷Patra, Greece
Somogy Megyei Kaposi Mór Oktató Kórház
🇭🇺Kaposvár, Hungary
CIMS Cancer, Care Institute of Medical Sciences, CIMS Hospital
🇮🇳Ahmedabad, Gujarat, India
Sahyadri Super Speciality Hospital
🇮🇳Pune, Maharashtra, India
The Chaim Sheba Medical Center
🇮🇱Ramat - Gan, Israel
U.O. Radiologia
🇮🇹Forli, Forli-cesena, Italy
Farmacia Oncologica
🇮🇹Meldola, Forli-cesena, Italy
U.O. Anatomia Patologica
🇮🇹Forli, Forli-cesena, Italy
Istituto Clinico Humanitas
🇮🇹Rozzano, Milan, Italy
AUSL della Romagna - RAVENNA, Presidio Ospedaliero di Faenza
🇮🇹Faenza, Ravenna, Italy
Presidio Ospedaliero San Donato
🇮🇹Arezzo, Italy
Centro di Riferimento Oncologico - IRCCS
🇮🇹Aviano (PN), Italy
S.O.C. di Farmacia
🇮🇹Aviano (PN), Italy
Presidio Ospedaliero di Lugo
🇮🇹Lugo, Ravenna, Italy
U.O. Farmacia Clinica - IDS
🇮🇹Bologna, Italy
Instituto Europeo di Oncologia
🇮🇹Milan, Italy
Servizio di Farmacia
🇮🇹Milan, Italy
Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS Fondazione Giovanni Pascale
🇮🇹Napoli, Italy
A.O.U. Pisana Ospedale S. Chiara
🇮🇹Pisa, Italy
Servizio Farmacia Ospedaliera - Farmacia Oncologica
🇮🇹Ravenna, Italy
Azienda Ospedaliera San Camillo Forlanini_Oncologia Medica
🇮🇹Rome, Italy
Presidio Ospedaliero di Ravenna
🇮🇹Ravenna, Italy
Azienda Ospedaliera S. Maria di Terni
🇮🇹Terni, Italy
Kobe City Medical Center General Hospital
🇯🇵Kobe-city, Hyogo, Japan
Tsukuba Medical Center Hospital
🇯🇵Tsukuba, Ibaraki, Japan
Iwate Medical University Hospital
🇯🇵Shiwa-gun, Iwate, Japan
National Hospital Organization Sagamihara National Hospital
🇯🇵Sagamihara, Kanagawa, Japan
Kindai University Hospital
🇯🇵Osakasayama, Osaka, Japan
Kanagawa cancer center
🇯🇵Yokohama, Kanagawa, Japan
Saitama Medical University International Medical Center
🇯🇵Hidaka, Saitama, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Koto-Ku, Tokyo, Japan
Yamaguchi University Hospital
🇯🇵Ube, Yamaguchi, Japan
National Hospital Organization Kyushu Cancer Center
🇯🇵Fukuoka, Japan
Osaka City University Hospital
🇯🇵Osaka, Japan
Kyushu University Hospital
🇯🇵Fukuoka, Japan
National Hospital Organization Kumamoto Medical Center
🇯🇵Kumamoto, Japan
Kagoshima University Hospital
🇯🇵Kagoshima, Japan
Yamagata University Hospital
🇯🇵Yamagata, Japan
Tokushima University Hospital
🇯🇵Tokushima, Japan
Niigata University Medical & Dental Hospital
🇯🇵Niigata, Japan
National Cancer Center - Clinical Trial Pharmacy
🇰🇷Goyang-si, Gyeonggi-do, Korea, Republic of
National Cancer Center Urology center for Prostate Cancer
🇰🇷Goyang-si, Gyeonggi-do, Korea, Republic of
Seoul National University Bundang Hospital, Clinical Pharmacy
🇰🇷Seongnam-si, Gyeonggido, Korea, Republic of
Chungnam National University Hospital, Clinical Pharmacy
🇰🇷Daejeon, Korea, Republic of
Chungnam National University Hospital
🇰🇷Daejeon, Korea, Republic of
Asan Medical Center - Clinical Trial Pharmacy
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center Clinical Trial Pharmacy
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Instituto Nacional de Cancerologia
🇲🇽Mexico, Ciudad DE Mexico, Mexico
Hospital Médica Campestre (Administradora Hospitalaria S.A de C.V.)
🇲🇽León, Guanajuato, Mexico
Radboud University Medical Center
🇳🇱Nijmegen, Netherlands
Rijnstate Arnhem
🇳🇱Arnhem, Netherlands
Ziekenhuis Rijnstate
🇳🇱Arnhem, Netherlands
Auckland City Hospital Pharmacy
🇳🇿Grafton, Auckland, New Zealand
Auckland City Hospital
🇳🇿Grafton, Auckland, New Zealand
Slade Health Inward Goods
🇳🇿Auckalnd, New Zealand
Christchurch Hospital
🇳🇿Christchurch, New Zealand
Waikato Hospital
🇳🇿Hamilton, New Zealand
Akershus University Hospital
🇳🇴Lorenskog, Norway
Sykehusapoteket HF 23 Lørenskog
🇳🇴Nordbyhagen, Norway
Stavanger University Hospital
🇳🇴Stavanger, Norway
Centralny Szpital Kliniczny MSWiA w Warszawie
🇵🇱Warszawa, Masovian, Poland
Centralny Szpital Kliniczny MSWiA
🇵🇱Warszawa, Masovian, Poland
Centrum Onkologii Ziemi Lubelskiej im. Sw. Jana z Dukli
🇵🇱Lublin, Poland
Lecznice CITOMED Sp. z o.o.
🇵🇱Torun, Poland
Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu
🇵🇱Torun, Poland
Wojewodzki Szpital Zespolony im. L. Rydygiera, Szpital Specjalistyczny dla Dzieci I Doroslych
🇵🇱Torun, Poland
Instituto Português de Oncologia de Coimbra Francisco Gentil, EPE
🇵🇹Coimbra, Portugal
Hospital Da Luz Coimbra, SA
🇵🇹Coimbra, Portugal
Centro Hospitalar de Lisboa Central, E.P.E. - Hospital de Santo António dos Capuchos
🇵🇹Lisboa, Portugal
Hospital CUF Descobertas, SA
🇵🇹Lisboa, Portugal
Dr. Campos Costa - Consultório de Tomografia Computorizada, S.A.
🇵🇹Porto, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, EPE
🇵🇹Porto, Portugal
Centro Hospitalar de São João, EPE
🇵🇹Porto, Portugal
Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE
🇵🇹Vila Real, Portugal
Dr. Campos Costa - Consultório de Tomografia Computorizada, S.A.- Matosinhos
🇵🇹Senhora da Hora, Portugal
State Budgetary Healthcare Insti. Republican Clinical Oncology Dispensary of the MoH of Bashk. Rep.
🇷🇺Ufa, Bashkortostan Republic, Russian Federation
Private Medical Institution "Evromedservice"
🇷🇺Pushkin, Saint Petersburg, Russian Federation
Moscow Research Oncology Institute named after P. A. Gertsen
🇷🇺Moscow, Russian Federation
BHI of Omsk region "Clinical oncological dispensary"
🇷🇺Omsk, Russian Federation
FGBIH "Clinical Hospital #122 n.a. L.G. Sokolov of Federal Medico-biological agency"
🇷🇺St. Petersburg, Russian Federation
University of Minnesota Medical Center
🇺🇸Minneapolis, Minnesota, United States
University of Minnesota
🇺🇸Minneapolis, Minnesota, United States
FSBEI HE "First St. Petersburg State Medical University n. a. academician l.P Pavlov" MoH RF
🇷🇺St. Petersburg, Russian Federation
FSBEI HE "First St. Petersburg State Medical University n.a. academician I.P Pavlov" MoH RF
🇷🇺St. Petersburg, Russian Federation
FSBEI HE "First St. Petersburg State Medical University n.a. academician I.P Pavlov"
🇷🇺St. Petersburg, Russian Federation
"Ramsay Diagnostics Rus", LLC
🇷🇺St. Petersburg, Russian Federation
FSBI "Russian Scientific Center For Radiology and Surgical Technologies n.a. Academician A.M. Granov
🇷🇺St. Petersburg, Russian Federation
Hospital Orkli, LLC
🇷🇺St. Petersburg, Russian Federation
Mart, Llc
🇷🇺St. Petersburg, Russian Federation
SHI YR "Regional Clinical Oncology Hospital"
🇷🇺Yaroslavl, Russian Federation
Institute for Oncology and Radiology of Serbia
🇷🇸Belgrade, Serbia
Clinical Centre Nis, Clinic of Oncology
🇷🇸Nis, Serbia
Oncology Institute of Vojvodina
🇷🇸Sremska Kamenica, Serbia
C.H. Univ. Santiago de Compostela
🇪🇸Santiago de Compostela, A Coruña, Spain
Hospital Universitario Germans Trias i Pujol
🇪🇸Badalona, Barcelona, Spain
Institut Catalá d'Oncología - Hospital Duran i Reynals
🇪🇸l´Hospitalet de LLobregat, Barcelona, Spain
Corporacio Sanitaria Parc Tauli
🇪🇸Sabadell, Barcelona, Spain
Hospital Clinico Universitario de Valencia
🇪🇸Valencia, Spain
Hospital General Universitario de Elche
🇪🇸Elche, Comunidad Valenciana, Spain
C. H. Universitario de Vigo- Hospital Álvaro Cunqueiro
🇪🇸Vigo, Galicia, Spain
C.H. Universitario de Vigo- Hospital Meixoeiro
🇪🇸Vigo, Galicia, Spain
Clinica Universidad de Navarra
🇪🇸Pamplona, Navarra, Spain
Hospital del Mar
🇪🇸Barcelona, Spain
Complejo Hospitalario de Navarra
🇪🇸Pamplona, Navarra, Spain
Hospital Vithas Internacional Medimar
🇪🇸Alicante, Spain
Hospital Universitario Infanta Cristina
🇪🇸Badajoz, Spain
Hospital Quiron
🇪🇸Barcelona, Spain
Hospital Quiron of Barcelona
🇪🇸Barcelona, Spain
Hospital de La Santa Creu i Sant pau_Oncology department
🇪🇸Barcelona, Spain
CETIR Grup Medic
🇪🇸Barcelona, Spain
Cetir, Centre Mèdic, S.L
🇪🇸Barcelona, Spain
Hospital Quirón de Barcelona
🇪🇸Barcelona, Spain
Hospital de La Santa Creu i Sant Pau
🇪🇸Barcelona, Spain
Hospital de Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Universitario Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Clinic de Barcelona
🇪🇸Barcelona, Spain
Hospital Universitario Reina Sofia
🇪🇸Cordoba, Spain
Laboratorio Dr. F. Echevarne Analisis, S.A
🇪🇸Barcelona, Spain
Hospital Universitario Reina Sofía
🇪🇸Cordoba, Spain
H. univ Girona Dr. Josep Trueta - lnstitut Catala d'Oncologia
🇪🇸Gerona, Spain
Hospital Universitario Lucus Augusti
🇪🇸Lugo, Spain
Institut Catala d'Oncologia
🇪🇸Gerona, Spain
Institut Diagnostic de la lmatge
🇪🇸Gerona, Spain
Gabinete Radiologico Doctor Pita
🇪🇸Madrid, Spain
Fundacion Maria Rafols para la investigacion del Diagnostico de la imagen
🇪🇸Madrid, Spain
Hospital General Universitario Gregorio Marañon
🇪🇸Madrid, Spain
Hospital Ruber Internacional
🇪🇸Madrid, Spain
Hospital Ruber International
🇪🇸Madrid, Spain
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Hospital Universitario Ramón y Cajal
🇪🇸Madrid, Spain
Hospital Clínico San Carlos
🇪🇸Madrid, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Hospital Universitario HM Sanchinarro - CIOCC
🇪🇸Madrid, Spain
Hospital Universitario Virgen del Rocio
🇪🇸Sevilla, Spain
Instituto Valenciano de Oncología
🇪🇸Valencia, Spain
APL
🇸🇪Stockholm, Sweden
Hospital Clínico Universitario de Valencia
🇪🇸Valencia, Spain
Karolinska University Hospital
🇸🇪Stockholm, Sweden
Clinical Trial Pharmacy, China Medical University Hospital
🇨🇳Taichung, Taiwan
Investigational Drug services, National Taiwan University Hospital
🇨🇳Taipei, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Koo Foundation Sun Yat-Sen Cancer Center
🇨🇳Taipei, Taiwan
Department of Pharmacy, National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
Pharmacy, Koo Foundation Sun Yat-Sen Cancer Center
🇨🇳Taipei, Taiwan
Chang Gung Memorial Hospital, Linkou
🇨🇳Taoyuan, Taiwan
Chemotherapy pharmacy, Chang Gung Memorial Hospital, Linkou
🇨🇳Taoyuan, Taiwan
Royal United Hospitals Bath NHS Foundation Trust
🇬🇧Bath, United Kingdom
St Bartholomew 's Hospital, Barts Health NHS Trust
🇬🇧London, United Kingdom
Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital
🇬🇧London, United Kingdom
Churchill Hospital, Oxford University Hospitals NHS Trust
🇬🇧Oxford, United Kingdom
Cleveland Clinic Foundation
🇺🇸Cleveland, Ohio, United States
Inova Schar Cancer Institute Infusion Pharmacy
🇺🇸Fairfax, Virginia, United States
Inova Schar Cancer Institute
🇺🇸Fairfax, Virginia, United States
Hospital Universitario Infanta Sofia
🇪🇸San Sebastián de los Reyes, Madrid, Spain
Centro de Investigación Clínica de Leon S.C.
🇲🇽Leon, Guanajuato, Mexico
Hospital Mãe de Deus/Aesc
🇧🇷Porto Alegre, RIO Grande DO SUL, Brazil
Dr Ram Manohar Lohia (RML) Hospital & PGI MER
🇮🇳New Delhi, Delhi, India
Fiona Stanley Hospital
🇦🇺Murdoch, Western Australia, Australia
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
Icon Cancer Care South Brisbane
🇦🇺South Brisbane, Queensland, Australia
Hospital Regional Dr. Enrique Vera Barros
🇦🇷La Rioja, Argentina
Centro de Investigacion Pergamino S.A.
🇦🇷Pergamino, Buenos Aires, Argentina
Hôpital Erasme
🇧🇪Bruxelles, Belgium
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
🇧🇷Sao Jose do Rio Preto, SP, Brazil
Sociedade Beneficente de Senhoras Hospital Sírio Libanês
🇧🇷São Paulo, SP, Brazil
Hopital de La Timone
🇫🇷Marseille, France
Icon Cancer Care Chermside
🇦🇺Chermside, Queensland, Australia
SA Pharmacy, Level 3 Pharmacy
🇦🇺Bedford Park, South Australia, Australia
GP Diagnostico SRL
🇦🇷La Rioja, Argentina
Instituto del Diagnostico
🇦🇷La Rioja, Argentina
Box Hill Hospital - Pharmacy Department, Bulding B, Loading Dock (access via Thames St)
🇦🇺Box Hill, Victoria, Australia
Hopital La Conception
🇫🇷Marseille cedex 5, France
Sotiria General Chest Disease Hospital
🇬🇷Athens, Greece
Farmacia Ospedaliera
🇮🇹Arezzo, Italy
AOU Ospedali Riuniti di Ancona
🇮🇹Torrette, Ancona, Italy
National Hospital Organization hokkaido Cancer Center
🇯🇵Sapporo,, Hokkaido, Japan
River City Pharmacy
🇦🇺Auchenflower, Queensland, Australia
Adelaide Cancer Centre
🇦🇺Kurralta Park, South Australia, Australia
AZ Klina - Apotheek
🇧🇪Brasschaat, Belgium
Hospital da Bahia
🇧🇷Salvador, BA, Brazil
Associacao Hospital de Caridade Ijui
🇧🇷Ijui, RS, Brazil
Hospital Israelita Albert Einstein - SP
🇧🇷São Paulo, SP, Brazil
CHUM - Centre Hospitalier de l'Universite de Montreal
🇨🇦Montréal, Quebec, Canada
Centre Leon Berard
🇫🇷Lyon cedex 8, France
The Townsville Hospital
🇦🇺Douglas, Queensland, Australia
Nova Pharmacy
🇦🇺Wendouree, Victoria, Australia
The Queen Elizabeth Hospital
🇦🇺Woodville South, South Australia, Australia
AZ Groeninge
🇧🇪Kortrijk, Belgium
Associação Educadora São Carlos - AESC / Hospital Mãe de Deus - Farmácia Oncológica
🇧🇷Porto Alegre, RS, Brazil
Hospital das Clinicas da Faculdade de Medicina da USP - HCFMUSP
🇧🇷Sao Paulo, SP, Brazil
Centre d'Oncologie et de Radiothérapie du Pays-Basque
🇫🇷Bayonne, France
Hopital Foch -Pharmacie
🇫🇷Suresnes, France
EUROMEDICA General Clinic of Thessaloniki
🇬🇷Thessaloniki, Greece
Kaposvári Egyetem Egészségügyi Centrum
🇭🇺Kaposvár, Hungary
Rajiv Gandhi Cancer Institute And Research Centre
🇮🇳Delhi, India
Hadassah University Hospital
🇮🇱Kiryat Hadassah, Jerusalem, Israel
UOSC Farmacia
🇮🇹Naples, Italy
National Hospital Organization Shikoku Cancer Center
🇯🇵Matsuyama, Ehime, Japan
Monash Medical Centre
🇦🇺East Bentleigh, Victoria, Australia
UZ Gent
🇧🇪Ghent, Belgium
CENOB Centro de Oncologia da Bahia S/S Ltda. / Oncovida
🇧🇷Salvador, BA, Brazil
Instituto Nacional de Câncer - INCA
🇧🇷Rio de Janeiro, RJ, Brazil
Centre Henri Becquerel
🇫🇷Rouen Cedex 1, France
Clinique Sainte Anne
🇫🇷Strasbourg, France
Farmacia Studi Clinici
🇮🇹Rozzano, Milan, Italy
Azienda Ospedaliero-Universitaria Policlinico S.Orsola Malpighi
🇮🇹Bologna, Italy
Fondazione IRCCS Istituto Nazionale Dei Tumori
🇮🇹Milan, Italy
Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli"
🇮🇹Naples, Italy
Nagoya University Hospital
🇯🇵Nagoya, Aichi, Japan
Gunma Prefectural Cancer Center
🇯🇵Ota, Gunma, Japan
Dokkyo Medical University Saitama Medical Center
🇯🇵Koshigaya, Saitama, Japan
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Gyeonggido, Korea, Republic of
Radboudumc
🇳🇱Nijmegen, Netherlands
Ballarat Day Procedure Centre
🇦🇺Wendouree, Victoria, Australia
CHU Nimes - Institut de Cancerologie du Gard
🇫🇷Nimes Cedex 9, France
CHU de Rouen - Hôpital Charles Nicolle
🇫🇷Rouen, France
Alexandra General Hospital, Oncology Department
🇬🇷Athens, Greece
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
🇮🇹Meldola, Forli-cesena, Italy
U.O.C. Farmacia
🇮🇹Rome, Italy
Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo
🇮🇹Candiolo, Torino, Italy
SC Farmacia
🇮🇹Milan, Italy
S.C. Farmacia Interna
🇮🇹Terni, Italy
Hirosaki University School of Medicine & Hospital
🇯🇵Hirosaki, Aomori, Japan
Hiroshima City Hiroshima Citizens Hospital
🇯🇵Hiroshima, Japan
Groupe Hospitalier Pitié Salpêtrière
🇫🇷Paris, France
Apollo Hospitals
🇮🇳Hyderabad, Telangana, India
CHU de Rouen
🇫🇷Rouen, France
Rambam Health Care Campus
🇮🇱Haifa, Israel
U.O.S. Medicina Nucleare
🇮🇹Forli, Forli-cesena, Italy
Hokkaido University Hospital
🇯🇵Sapporo, Hokkaido, Japan
Keio University Hospital
🇯🇵Shinjuku-Ku, Tokyo, Japan
IRCCS Ospedale Policlinico San Martino
🇮🇹Genova, Liguria, Italy
St Apotheek der Haarlemse Ziekenhuizen
🇳🇱Haarlem, Netherlands
Spaarne Gasthuis
🇳🇱Hoofddorp, Netherlands
China Medical University Hospital
🇨🇳Taichung, Taiwan
Severance Hospital Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Nihon University Itabashi Hospital
🇯🇵Itabashi-ku, Tokyo, Japan
Hamamatsu University School of Medicine, University Hospital
🇯🇵Hamamatsu, Shizuoka, Japan
Phylasis Clinicas Research S. de R.L. de C.V.
🇲🇽Cuautitlan Izcalli, Estado DE Mexico, Mexico
Maastricht University Medical Center
🇳🇱Maastricht, Netherlands
Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu Szpital Obserwacyjno-Zakazny
🇵🇱Torun, Poland
Non-State Healthcare Institution "Railway Clinical Hospital JSC RZhD"
🇷🇺St. Petersburg, Russian Federation
Hospital Comarcal General de Elda de Virgen de la Salud
🇪🇸Elda, Alicante, Spain
Federal State Budgetary Institution "National medical research radiology center" MoH RF
🇷🇺Obninsk, Kaluzhskaya Region, Russian Federation
Institut Catalá d'Oncología
🇪🇸L´Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario Central de Asturias
🇪🇸Oviedo, Asturias, Spain
Principal Military Clinical Hospital n.a. N.N. Burdenko
🇷🇺Moscow, Russian Federation
Althaia. Xarxa Assistencial Universitaria de Manresa
🇪🇸Manresa, Barcelona, Spain
Cleveland Clinic Taussing Cancer Center
🇺🇸Cleveland, Ohio, United States
Seattle Cancer Care Alliance
🇺🇸Seattle, Washington, United States
S.C. Farmacia Ospedaliera
🇮🇹Napoli, Italy
Aalborg Universitetshospital Syd
🇩🇰Aalborg, Denmark
Aalborg Universitetshospital
🇩🇰Aalborg, Denmark
Sygehusapoteket Aalborg
🇩🇰Aalborg, Denmark
Aarhus Universitetshospital
🇩🇰Aarhus N, Denmark
Rigshospitalet, Onkologisk Klinik, afsnit 5073
🇩🇰Copenhagen OE, Denmark
Herlev Hospital
🇩🇰Herlev, Denmark
Herlev og Gentofte Hospital
🇩🇰Herlev, Denmark
Klinik for Klinisk Fysiologi,Nuklearmedicin og PET
🇩🇰København Ø, Denmark
Rigshospitalet
🇩🇰København Ø, Denmark
Assaf Harofe MC
🇮🇱Beer Yaakov, Israel
Sykehusapoteket Lorenskog
🇳🇴Nordbyhagen, Norway
Chiba Cancer Center
🇯🇵Chiba, Japan
St. Bartholomew's Hospital, Barts Health NHS Trust
🇬🇧London, United Kingdom
Guy's & St. Thomas' NHS Foundation Trust
🇬🇧London, United Kingdom
Anschutz Cancer Center Pavilion Pharmacy
🇺🇸Aurora, Colorado, United States
University of Colorado Cancer Center
🇺🇸Aurora, Colorado, United States
University of Colorado Denver, CTO (CTRC)
🇺🇸Aurora, Colorado, United States
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
🇺🇸Aurora, Colorado, United States
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
🇺🇸Aurora, Colorado, United States
Macquarie University
🇦🇺Macquarie University, New South Wales, Australia
Sunshine Coast University Hospital
🇦🇺Birtinya, Queensland, Australia
Smilow Cancer Hospital at Yale New Haven
🇺🇸New Haven, Connecticut, United States
Smilow Cancer Hospital at Yale-New Haven
🇺🇸New Haven, Connecticut, United States
Box Hill Hospital
🇦🇺Box Hill, Victoria, Australia
BHS Diagnostic Services
🇦🇺Ballarat, Victoria, Australia
Lake Imaging
🇦🇺Ballarat, Victoria, Australia
Cancer Care SA Pty Ltd
🇦🇺Kurralta Park, South Australia, Australia
Icon Cancer Care SA trading as Icon Pharmacy Adelaide
🇦🇺Kurralta Park, South Australia, Australia
Medica Superspecialty hospital
🇮🇳Kolkata, WEST Bengal, India
Icon Cancer Care Southport
🇦🇺Southport, Queensland, Australia
Department of Clinical Oncology
🇭🇰Hong Kong, Hong Kong